patents aren’t... important in emerging markets. It’s... brand name.
Any guess how much copy-cats or counterfeits, with good copies of labels and nearly nil FDA oversight from a few places such as China, South America, etc., would affect the generic or branded market?
Or are you making the case, or explaining the reality, for the humanitarian and economic reasons to make critical drugs available at low cost in developing countries to substantially improve their quality of life and ability to return the favor at some point in the future?
Market Data 
Markets 
AI
